EU pharma stakeholders take action to tackle fake medicines



A number of pharma stakeholders announced on 9 February the official launch of the European Medicines Verification System (EMVS), which will make use of new technologies to improve safety in the medicines’ supply chain against fake products.

The new system is part of the Falsified Medicines Directive (FMD) and is managed by consortia of stakeholders, ranging from pharma manufacturers, both innovative and generic pharma industry, to wholesalers, community pharmacists, hospitals and hospital pharmacies.

According to the European Medicines Authority (EMA), falsified medicines are fake medicines designed to mimic real medicines. Surveys suggest that the prevalence of counterfeit medicines in the legal supply chain in Europe is approximately 0.005%.

The European Commission says fake medicines pose a severe threat to patients, considering that they may contain ingredients of bad quality or in the wrong dosage.

CONTINUE READING ON www.euractiv.com

                   

Related News

Loading...